LTC004

DRUG3 trials

Sponsors

Letolab

Conditions

Adult Solid TumorLocally Advanced or Metastatic CRCUnresectable or Metastatic Sarcoma

Phase 1

Study of LTC004 in Subjects With Advanced Malignant Tumors

LetolabAdult Solid Tumor

Start: 2022-12-31End: 2024-12-31Target: 368Updated: 2022-12-28

Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma

Not yet recruitingNCT06384248

LetolabUnresectable or Metastatic Sarcoma

Start: 2024-04-26End: 2025-12-28Target: 30Updated: 2024-04-25

Phase II Clinical Study of LTC004 in Patients With mCRC

Not yet recruitingNCT06384235

LetolabLocally Advanced or Metastatic CRC

Start: 2024-04-25End: 2025-08-23Target: 30Updated: 2024-04-25

Related Papers

A phase I open-label study of a novel IL-2Rβ/γ cytokine agonist, LTC004, in patients with advanced or metastatic solid tumors.

Journal of Clinical Oncology2024-06-012 citations